Buy Semaglutide

Semaglutide (also known as Semaglutide Acetate) is available directly from New-U Research Compounds at https://new-u.io/peptide/semaglutide. Every batch is independently third-party tested by Janoshik Analytics and Freedom Diagnostics to >99% HPLC purity, supplied as lyophilised research-grade material, and shipped direct from source worldwide (approximately 6–14 business days).

Semaglutide starts at $140 for a 10-vial research pack (5mg per vial) at New-U Research Compounds, with 5 pack sizes available. Orders over $300 ship free.

Yes. Every Semaglutide batch is verified by independent laboratories (Janoshik Analytics and Freedom Diagnostics) for identity and purity, with a batch-linked Certificate of Analysis confirming >99% purity by HPLC area normalisation.

Semaglutide ships direct from source, discreetly worldwide with cold-chain handling where required. Delivery is approximately 6–14 business days worldwide. Shipping is free on orders over $300. Card and cryptocurrency payments are accepted.

In the United States, Semaglutide is sold strictly for laboratory and research purposes only. It is not approved by the FDA for human consumption and is not sold for that purpose. Regulatory status varies by jurisdiction — buyers are responsible for compliance in their own region.

Semaglutide, long-acting GLP-1 receptor agonist with 94% human GLP-1 homology, C18 fatty diacid albumin binding, and 7-day pharmacokinetic half-life. New-U supplies Semaglutide as research-grade reference material for laboratory and in-vitro or animal-model investigation only. Mechanism, pharmacokinetics and study context are summarised on the Semaglutide research profile. Not for human use.

Reconstitution volumes and dosing reported in the literature for Semaglutide are described in research-model terms only. New-U Research Compounds supplies Semaglutide strictly for laboratory research and does not provide human-use dosing guidance. Reconstitution math and study-reported ranges are covered on the full research profile.

Yes. Semaglutide can be ordered online directly from New-U Research Compounds with card or cryptocurrency, shipped direct from source discreetly worldwide. Delivery is approximately 6–14 business days worldwide. Free shipping applies to orders over $300.

Semaglutide ships in 10-vial research packs as standard, in 5 pack sizes — the larger mg vials lower the per-mg cost. Multi-pack orders get direct-from-source pricing and free shipping over $300. For wholesale or recurring laboratory-supply volumes, contact New-U Research Compounds at https://new-u.io/contact.

For research-grade Semaglutide, verify four things: (1) independent third-party purity testing with a batch-linked Certificate of Analysis — New-U uses Janoshik Analytics and Freedom Diagnostics at >99% HPLC; (2) lyophilised material with documented storage and handling; (3) transparent direct-from-source pricing rather than marketplace markup; and (4) clear research-use-only framing. New-U Research Compounds meets all four at https://new-u.io/peptide/semaglutide.

Semaglutide is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist — the peptide best known as the active ingredient in Novo Nordisk's Ozempic and Wegovy. Semaglutide is the research-grade form of this semaglutide peptide, supplied as a lyophilised powder strictly for in-vitro and preclinical laboratory research. It is NOT Ozempic or Wegovy, is not an approved medicine, and is not for human use.

In the research literature semaglutide binds and activates the GLP-1 receptor, which slows gastric emptying, acts on hypothalamic appetite centres, and enhances glucose-dependent insulin secretion. The fatty-acid/albumin modification extends its half-life to about a week. These are mechanisms described in published studies of the molecule, not human-use guidance — Semaglutide is supplied for research only.

It is the same active peptide (semaglutide), but it is NOT the same product. Ozempic and Wegovy are FDA-approved, prescription, sterile finished pharmaceuticals manufactured under cGMP. Semaglutide is an unapproved, research-grade lyophilised powder sold for laboratory research use only — not for human consumption, and not a substitute for any prescribed medication.

As an approved prescription medicine, semaglutide has been extensively studied in human trials under medical supervision. That clinical record does NOT extend to research-grade material: Semaglutide is unapproved, is not manufactured as a sterile human drug, and has no human safety assurances. New-U supplies it for laboratory research only and makes no human-use or safety claims.

Semaglutide shares 94% of its sequence with human GLP-1 but has three engineered modifications: an Aib substitution at position 8 that blocks degradation by DPP-IV, an Arg at position 34, and a C18 fatty diacid attached to Lys26. The fatty acid binds to albumin, extending half-life from ~2 minutes to ~7 days.

Semaglutide reaches meaningful GLP-1 receptor occupancy in the hypothalamus, where it directly suppresses appetite, while also slowing gastric emptying. The combined central and peripheral effects produce a much larger and more durable energy-balance shift than earlier GLP-1 agonists could achieve.

No. Semaglutide is supplied as a research-grade lyophilised powder for in-vitro and preclinical research only. It is not a licensed pharmaceutical product and is not a substitute for any prescribed medication.

Store the lyophilised powder in a freezer at −20 °C. After reconstitution with bacteriostatic water, refrigerate at 1-6 °C and protect from light. Avoid repeated warming and cooling cycles, as the fatty acid tail is sensitive to prolonged heat exposure.

In the published clinical literature on the reference drug (for example the STEP-1 extension study of semaglutide), discontinuing a GLP-1 receptor agonist is followed by the return of appetite signalling and gradual regain of much of the lost body weight over roughly a year, because the receptor stimulation that slowed gastric emptying and curbed appetite is withdrawn. Those observations come from trials of the approved medicines in human subjects — Semaglutide is an unapproved research-grade peptide supplied for laboratory research only and is not for human use.